CardioSource WorldNews | Page 7
LIVE
COURSES
2016
January 16–20
June 04–07
June 17–18
The Westin Snowmass Resort
Snowmass, CO
Mexico City, Mexico
The Westin Houston
Memorial City
Houston, TX
Cardiovascular Conference
at Snowmass: Contemporary
Approaches to Clinical Care
World Heart Federation |
World Congress of Cardiology
& Cardiovascular Health 2016
Care of the Athletic Heart:
Translating Clinical Science
into Practice Strategies
B:7.875 in
February 06–07
T:7.5 in
S:7 in
2016 Women in Cardiology
(WIC) Section Leadership
Workshop
Add Corlanor ® to maximally tolerated doses of beta-blockers and help give
Heart House
Washington, DC
appropriate patients with heart rate ≥ 70 bpm and stable, symptomatic chronic HF...
MORE HOME. LESS HOSPITAL.
February 15–19
38th Annual Cardiology at
Big Sky
Huntley Lodge
Big Sky, MT
February 18–20
Learn how you can DO MORE with Corlanor® to reduce the risk
of hospitalization for worsening heart failure (HF)
2016 Cardiovascular Summit:
Solutions for Thriving in a
Time of Change
1
CorlanorHCP.com
The Cosmopolitan of Las Vegas
Las Vegas, NV
April 02–04
ACC.16 65th Annual Scientific
Session & Expo
McCormick Center
Chicago, IL
May 05–07
Recent Advances in Clinical
Nuclear Cardiology and
Cardiac CT: State of the Art
Updates and 101 EvidenceBased Case Reviews
Capital Hilton
Washington, DC
Review Live Courses
and Meetings at
ACC.org by scanning
the code.
Indication
Corlanor® (ivabradine) is indicated to reduce the risk of hospitalization
for worsening heart failure in patients with stable, symptomatic
chronic heart failure with left ventricular ejection fraction ≤ 35%, who
are in sinus rhythm with resting heart rate ≥ 70 beats per minute and
either are on maximally tolerated doses of beta-blockers or have a
contraindication to beta-blocker use.
Important Safety Information
Contraindications: Corlanor® is contraindicated in patients with
acute decompensated heart failure, blood pressure < 90/50 mmHg,
sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular
block (unless a functioning demand pacemaker is present), a resting
heart rate < 60 bpm prior to treatment, severe hepatic impairment,
pacemaker dependence (heart rate maintained exclusively by the
pacemaker), and concomitant use of strong cytochrome P450 3A4
(CYP3A4) inhibitors.
Fetal Toxicity: Corlanor® may cause fetal toxicity when administered
to a pregnant woman based on embryo-fetal toxicity and cardiac
teratogenic effects observed in animal studies. Advise females to use
effective contraception when taking Corlanor®.
Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation.
The rate of atrial fibrillation in patients treated with Corlanor®
compared to placebo was 5% vs. 3.9% per patient-year, respectively.
Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial
fibrillation develops.
© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-115485 11-15
Bradycardia and Conduction Disturbances: Bradycardia, sinus
arrest and heart block have occurred with Corlanor®. The rate of
bradycardia in patients treated with Corlanor® compared to placebo
was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per
patient-year, respectively. Risk factors for bradycardia include sinus
node dysfunction, conduction defects, ventricular dyssynchrony, and
use of other negative chronotropes. Concurrent use of verapamil or
diltiazem also increases Corlanor® exposure, contributes to heart rate
lowering, and should be avoided. Avoid use of Corlanor® in patients
with 2nd degree atrioventricular block unless a functioning demand
pacemaker is present.
Adverse Reactions: The most common adverse drug reactions reported
at least 1% more frequently with Corlanor® than placebo and that
occurred in more than 1% of patients treated with Corlanor® were
bradycardia (10% vs. 2.2%), hypertension or increased blood pressure
(8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous
phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%).
Please see Brief Summary of full Prescribing Information
on adjacent page.
BPM = beats per minute; HF = heart failure.
Reference: 1. Corlanor® (ivabradine) Prescribing Information, Amgen.